Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation [Phase 2]
Phase 2 trial updating patients with chronic myeloid leukemia who switched from imatinib to nilotinib and then underwent treatment cessation…
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene [Phase 1, Phase 2]
Clinical trial update evaluating tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 in adults with Ph+ chronic myeloi…
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase [Phase 2]
A Phase 2 trial evaluated the combination of dasatinib and peg-interferon alfa-2b as first-line therapy for chronic phase chronic myeloid le…
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts [Phase 2]
A Phase 2 clinical trial evaluating T cell depletion in recipients of HLA haploidentical related donor stem cell grafts for various hematolo…
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT [Phase 1]
Phase 1 trial exploring a calcineurin inhibitor-free graft-versus-host disease prevention regimen after related haploidentical peripheral bl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-01-10Clinical Trial Update: Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial evaluating fludarabine phosphate with low-dose total-body irradiation and peripheral blood stem cell transplant, fo…
-
FDA approval · 2020-01-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate from Teva Pharmaceuticals USA, Inc., under ANDA204285.
-
CLINICAL_TRIALS trial_result · 2019-12-20Clinical Trial Update: Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation [Phase 4]
Phase 4 trial update on Chronic Myelogenous Leukemia (CML) evaluating compliance and optimization strategies.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients [Phase 4]
Phase 4 trial update evaluating digital-PCR analysis during interrupted imatinib therapy in PCR-negative chronic myeloid leukemia patients.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years [Phase 3]
Phase 3b open-label randomized study in chronic myeloid leukemia investigating confirmed molecular response rate over two years; trial termi…
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: Treatment-free Remission Accomplished With Dasatinib in Patients With CML [Phase 2]
Phase 2 trial reporting treatment-free remission achieved with dasatinib in chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
-
FDA approval · 2019-10-09FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for BOSULIF (bosutinib) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2019-09-11Clinical Trial Update: Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) [Phase 2]
Phase II trial updating nilotinib use in newly diagnosed chronic phase chronic myeloid leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) [Phase 2]
Phase 2 trial evaluating ponatinib as frontline therapy for chronic myeloid leukemia in accelerated phase; the study was terminated and resu…
-
CLINICAL_TRIALS research · 2019-09-06Clinical Trial Update: Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Clinical trial assessing electrophysiological biomarkers of chemotherapy-related cognitive impairment and recovery; study completed with pos…
-
CLINICAL_TRIALS trial_result · 2019-08-19Clinical Trial Update: A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase [Phase 3]
Phase 3 trial update on imatinib and nilotinib in chronic myeloid leukemia in chronic phase; results posted after completion.
-
FDA approval · 2019-08-14FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Bosulif (bosutinib) submitted by Pfizer Laboratories Div Pfizer Inc, signaling an update to the …
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating consolidation treatment with ponatinib 15 mg on treatment-free remission rates in patients with chronic my…
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 clinical trial evaluating nilotinib in combination with pegylated interferon alpha-2a for untreated chronic phase chronic myeloid le…
-
CLINICAL_TRIALS trial_result · 2019-05-01Clinical Trial Update: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies [Phase 2]
Phase 2 clinical trial evaluating BL-8040 for mobilizing donor hematopoietic stem cells to enable allogeneic transplantation in patients wit…
-
FDA approval · 2019-04-18FDA Approved: BUSULFAN — Original Application (Armas Pharmaceuticals Inc.)
FDA approved a generic Busulfan from Armas Pharmaceuticals Inc. under ANDA210931, enabling a generic formulation.
-
CLINICAL_TRIALS trial_result · 2019-04-11Clinical Trial Update: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib [Phase 2]
Phase 2 trial comparing dasatinib to imatinib in patients with chronic phase chronic myeloid leukemia who did not respond favorably to imati…
-
CLINICAL_TRIALS research · 2019-03-12Clinical Trial Update: Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia [Phase 1, Phase 2]
A clinical trial evaluating the safety and feasibility of natural killer cells in patients with chronic myeloid leukemia in Phase 1/Phase 2.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) [Phase 2]
Phase 2 study evaluating novel approaches to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation, with res…